naultjc.bsky.social @naultjc.bsky.social · 27/11/2025📌 Conclusion: The new Atezolizumab–Bevacizumab–Cluster (A-B-C) classification captures biological + prognostic heterogeneity in unresectable HCC. A tool to refine trial design, enrich populations, and personalize treatments. 000
naultjc.bsky.social @naultjc.bsky.social · 27/11/2025Outcomes were strikingly distinct: 🔹 A had best OS (median not reached), lowest progression (25%), longest PFS (~11 mo). 🔸 B OS ~18 mo 🔸 C OS ~14 mo Patterns held across BCLC stages + early hepatic decompensation risk. 100
naultjc.bsky.social @naultjc.bsky.social · 27/11/2025Tumor biology differed: Cluster C showed poorer differentiation and more macrotrabecular-massive subtype → consistent with aggressive disease biology. 100
naultjc.bsky.social @naultjc.bsky.social · 27/11/2025Three clusters emerged: 🔹 A (47.5%) – older, higher BMI, good liver function, multiple small tumors. 🔹 B (11%) – VP1/2 PVI, more HBV, fewer metabolic features. 🔹 C (41.2%) – worse liver function, high AFP, VP3/4 PVI or large tumor burden. 100
naultjc.bsky.social @naultjc.bsky.social · 27/11/20251) We recently published a multicentric study in cghjournal.org/article/S154... We analyzed using machine learning an international cohort of 1,399 pts treated for HCC with atezo/bev across 12 centers to uncover clinically meaningful subgroups. @etrepo.bsky.socialcghjournal.orgThe “A-B-C” classification reveals outcome trajectories in patients with hepatocellular carcinoma under atezolizumab/bevacizumabWe aimed to identify subgroups of patients with unresectable hepatocellular carcinoma (HCC) using a non‐a priori, data‐driven machine learning approach to uncover subgroups with distinct profiles acro... 122
naultjc.bsky.social @naultjc.bsky.social · 23/11/20256) Immunohistochemistry: PCT is positive in 77% of FLC, but absent in other primary or secondary liver tumors. In conclusion 👉 serum and tumor PCT = sensitive & specific biomarker for fibrolamellar hepatocellular carcinoma. 011
naultjc.bsky.social @naultjc.bsky.social · 23/11/20255) CALCA (the PCT gene) is strongly overexpressed in FLC and spatial transcriptomics localizes CALCA to tumor cells. 100
naultjc.bsky.social @naultjc.bsky.social · 23/11/20254) In 4 FLC patients, PCT tracked RECIST response under systemic treatment: ↓ in partial response, ↑ in progression, ↔ in stable disease. A promising dynamic monitoring marker. 110
naultjc.bsky.social @naultjc.bsky.social · 23/11/20253) Serum PCT is markedly elevated in FLC vs HCC, CCA or cirrhosis, in both EU & US cohorts. 👉 83% high PCT in FLC vs 0 to 3% in HCC or CCA. 100
naultjc.bsky.social @naultjc.bsky.social · 23/11/20252) Fibrolamellar carcinoma (FLC) affects young patients and lacks reliable biomarkers (AFP/CA19-9 usually normal). An unexpectedly high PCT level in one case led us to investigate PCT across two cohorts (Europe and USA) 100
naultjc.bsky.social @naultjc.bsky.social · 23/11/20251) We recently identified as serum tumor biomarker of fibrolamellar carcinoma, procalcitonin, with @zucmanrossi.bsky.social and @markyarchoan.bsky.social that you can find in www.medrxiv.org/content/10.1...medrxiv.orgSerum Procalcitonin: A Novel Tumor Biomarker for Diagnosis and Follow-Up in Fibrolamellar Hepatocellular CarcinomaIntroduction: Fibrolamellar carcinoma (FLC) is a rare primary liver cancer that predominantly affects young patients with normal known serum tumor biomarkers (alpha-fetoprotein (AFP) and CA19-9). An o... 132
naultjc.bsky.social @naultjc.bsky.social · 20/11/2025Claudia Campani from Cordeliers Research Center received Best clinical poster award in @ILCAnews meeting in Hong Kong 000
naultjc.bsky.social @naultjc.bsky.social · 20/11/2025Claudia Campani presenting our work on Molecular based therapy in primary liver cancer refractory to systemic treatments in ILCA meeting in Hong Kong 010
naultjc.bsky.social @naultjc.bsky.social · 16/09/2025Our work about « Molecular based targeted therapies in primary liver cancers » presented by Claudia Campani at ESMO precision medicine @myesmo.bsky.social 020
Reposted by @naultjc.bsky.socialNature Genetics @natgenet.nature.com · 08/07/2025📢ONLINE @natgenet.nature.com 📰Cytidine diphosphate diacylglycerol synthase 2 is a synthetic lethal target in mesenchymal-like cancers. By Tim Arnoldus, Daniel S. Peeper and colleagues. ⬇️ www.nature.com/articles/s41...nature.comCytidine diphosphate diacylglycerol synthase 2 is a synthetic lethal target in mesenchymal-like cancers - Nature GeneticsThe paralogs cytidine diphosphate diacylglycerol synthase 1 and 2 form a potentially targetable synthetic lethal relationship in mesenchymal-like cancers that involves disruption of lipid metabolism. 141
naultjc.bsky.social @naultjc.bsky.social · 19/06/2025Pr Éric Trepo on genetic prédisposition to HCC on alcohol related liver Disease in the Paris Liver Cancer Group Day, June 2025 010
naultjc.bsky.social @naultjc.bsky.social · 30/05/2025www.nature.com/articles/s41...nature.comThe pivot penalty in research - NatureAn analysis of millions of scientific papers and patents reveals a ‘pivot penalty’ when researchers shift direction, with the impact of studies decreasing rapidly the further they move from their prev... 000
naultjc.bsky.social @naultjc.bsky.social · 25/04/20257/ In conclusion, Systematic biopsies during RFA = safe + informative. They can sharpen diagnosis, guide therapy & predict prognosis in newly diagnosed HCC. #HCC #LiverCancer #Biopsy 100
naultjc.bsky.social @naultjc.bsky.social · 25/04/20256/ 🧾 Non-tumor biopsy insights 82% showed histological cirrhosis, but 15% had discrepancies with tumor board diagnosis—underlining the clinical relevance of liver biopsies beyond the tumor. 100
naultjc.bsky.social @naultjc.bsky.social · 25/04/20255/ 🧬 Biopsy for molecular analysis Samples with >25% tumor cells enabled transcriptomic analysis, validating their use for future molecular profiling and personalized treatment strategies. 100
naultjc.bsky.social @naultjc.bsky.social · 25/04/20254/ ⚠️ Prognostic implications Biopsy uncovered 3% cholangiocarcinoma/hepatocholangiocarcinoma—linked to significantly shorter survival. Also, macrotrabecular-massive HCC subtype had higher recurrence (P=0.037). 100
naultjc.bsky.social @naultjc.bsky.social · 25/04/20253/ 🔬 Diagnostic value Tumor biopsy confirmed HCC in 66% of cases. Diagnostic yield was better with: ✔️ Larger nodules ✔️ Peripheral location ✔️ Good ultrasound visibility 34% were non-diagnostic, 5% differed from prior board diagnosis (hepatocholangiocarcinoma, cholangiocarcinoma, dysplastic nodules) 100
naultjc.bsky.social @naultjc.bsky.social · 25/04/20252/We looked in 248 patients at safety, diagnostic yield & prognostic insights from tumor + non-tumor biopsies. ✅ Safety first Biopsies done during RFA had a low complication rate: 🔹 Bleeding in only 1.9% of cases 🔹 No biopsy-related deaths 100
naultjc.bsky.social @naultjc.bsky.social · 25/04/2025🧵1/ Can systematic biopsies during RFA improve how we diagnose & manage hepatocellular carcinoma (HCC)? Our study was recently published in J hep reports. Here's what we found 👇 www.jhep-reports.eu/article/S258...jhep-reports.euUtility of tumor and non-tumor biopsies during percutaneous radiofrequency ablation for hepatocellular carcinomaWe aim to assess the safety and diagnostic/prognostic value of tumor and non-tumor biopsies systematically collected during radiofrequency ablation (RFA) of hepatocellular carcinoma (HCC). 132
Reposted by @naultjc.bsky.socialRob Brierley @robbrierley.bsky.social · 21/02/2025Routine [18F]FCH and [18F]FDG PET-CT for tumour staging in all patients with a 1st diagnosis of hepatocellular carcinoma has limited clinical value Guidelines should continue to emphasise morphological imaging (eg MRI & CT) for staging #OncSky #MedSky @oncoalert.bsky.social @naultjc.bsky.social 043
Reposted by @naultjc.bsky.socialThe Lancet Gastroenterology & Hepatology @lancetgastrohep.bsky.social · 21/02/2025New research - Nault et al - [¹⁸F]fluorodeoxyglucose and [¹⁸F]fluorocholine PET-CT for staging optimisation and treatment modification in hepatocellular carcinoma (PET-HCC01): a prospective multicentre study buff.ly/419ebHP #MedSky #OncSky #LiverSky @naultjc.bsky.social 021
naultjc.bsky.social @naultjc.bsky.social · 04/02/2025www.thelancet.com/journals/lan...thelancet.comCommon Sense Oncology principles for the design, analysis, and reporting of phase 3 randomised clinical trialsCommon Sense Oncology (CSO) prioritises treatments providing meaningful benefits for people with cancer. Here, we describe CSO principles aimed at improving the design, analysis, and reporting of rand... 010
Reposted by @naultjc.bsky.socialRob Brierley @robbrierley.bsky.social · 15/01/2025New research - Aspirin after completion of standard adjuvant therapy for colorectal cancer (ASCOLT): an international, multicentre, phase 3, randomised, double-blind, placebo-controlled trial www.thelancet.com/journals/lan... #GastroSky #OncSky #MedSky @oncoalert.bsky.social 095
naultjc.bsky.social @naultjc.bsky.social · 19/12/2024www.nature.com/articles/s41...nature.comEngineered extrachromosomal oncogene amplifications promote tumorigenesis - NatureLarge extrachromosomal DNAs are engineered using a CRISPR- and Cre–loxP-based approach and shown to drive cancer in mouse models, with potential applications in determining the role of oncogene a... 000
